- Home
- APLM vs IBG Comparison
APLM vs IBG Comparison
Compare APLM & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- IBG
- Stock Information
- Founded
- APLM 2016
- IBG 2018
- Country
- APLM United States
- IBG Australia
- Employees
- APLM N/A
- IBG N/A
- Industry
- APLM Blank Checks
- IBG Beverages (Production/Distribution)
- Sector
- APLM Finance
- IBG Consumer Staples
- Exchange
- APLM Nasdaq
- IBG Nasdaq
- Market Cap
- APLM 6.9M
- IBG 6.0M
- IPO Year
- APLM N/A
- IBG 2024
- Fundamental
- Price
- APLM $6.14
- IBG N/A
- Analyst Decision
- APLM
- IBG Strong Buy
- Analyst Count
- APLM 0
- IBG 1
- Target Price
- APLM N/A
- IBG N/A
- AVG Volume (30 Days)
- APLM 7.8K
- IBG 89.6K
- Earning Date
- APLM 08-13-2025
- IBG 07-11-2025
- Dividend Yield
- APLM N/A
- IBG N/A
- EPS Growth
- APLM N/A
- IBG N/A
- EPS
- APLM N/A
- IBG N/A
- Revenue
- APLM $198,000.00
- IBG $2,931,243.00
- Revenue This Year
- APLM $415.15
- IBG N/A
- Revenue Next Year
- APLM N/A
- IBG N/A
- P/E Ratio
- APLM N/A
- IBG N/A
- Revenue Growth
- APLM N/A
- IBG N/A
- 52 Week Low
- APLM $4.47
- IBG $0.44
- 52 Week High
- APLM $35.98
- IBG $3.35
- Technical
- Relative Strength Index (RSI)
- APLM 47.85
- IBG N/A
- Support Level
- APLM $6.21
- IBG N/A
- Resistance Level
- APLM $6.80
- IBG N/A
- Average True Range (ATR)
- APLM 0.52
- IBG 0.00
- MACD
- APLM 0.00
- IBG 0.00
- Stochastic Oscillator
- APLM 51.61
- IBG 0.00
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.